Pfizer Throws In the Lipitor Marketing Towel. Meanwhile AstraZeneca Promotes Crestor on Its Corporate...
Despite Pfizer's heroic and unprecedented effort to maintain Lipitor's market share after expiry last November and after spending more than $87 million promoting the medicine, the world's biggest drug company is quietly giving up on its once-great cash cow for good because more generic versions will soon be going on sale. Meanwhile, AstraZeneca promoted Crestor on its corporate blog. It's unusual for a pharmaceutical company to mention a product by brand name on its corporate blog. It's even more unusual to mention BOTH the product AND its indication -- because that would be promotion regulated by the FDA. But AstraZeneca has done just that on its 'AZ Health Connections' corporate blog. Why now? Can it be a purely opportunistic cheap shot?
Google launched a new drug search result format that includes data from the U.S. FDA, the National Library of Medicine, and the Department of Veterans Affairs, among othersbut apparently not directly from pharmaceutical companies.
On the one hand, there's the physician who's looking for 'evidence' that diabetes is being managed. On the other hand is the patient argument that 'emotional support' is also a key benefit. One could argue that BOTH sides have merit.
Pharma marketers in the U.S. sometimes use celebrities as spokespeople for their branded drugs or for non-branded campaigns. Such celebrities include TV personalities, athletes, movie stars and others who have thousands or millions of fans, Twitter followers, etc. Should Pharma Disclose Payments to Celebrity Spokespeople? This is just one of the issues explored in a recent survey of Pharma Marketing News readers.
How is the iPad a proven effective sales message delivery platform? What impact does it have on a doctor's clinical and prescribing decision-making process? These are questions that MD Mindset's proprietary iSFE Tracker(tm) methodology is designed to answer.
FDA Plans to Do Two Studies to Find Out
What's at Stake in the Off-Label Debate Freedom of speech may be the legal issue, but enhancing the bottom line is the business issueIn...
There's a lot of brouhaha these days in pharma circles about 'gamification' as if it were the newest thing since sliced bread. These days, however, it may be easier for a pharma company to create a real-life museum educational gaming experience than a virtual world game on Facebook. Way back in 1984, gamification was much simpler.
PharmaGuy (aka John Mack) presented the coveted bright yellow Hawaiian shirt/Pharmaguy Social Media Pioneer Award to Dennis Urbaniak, VP, Joan Mikardos, Senior Director, and Laura Kolodjeski, Senior Manager, Patient Solutions, at Sanofi US Diabetes. The award was made at the 6th Annual Digital Pharma East conference in Philadelphia on October 17, 2012. Accepting the award on behalf of the winners -- who could not make it in person -- was Wendy Blackburn of Intouch Solutions.
As reported by Nielsen, direct-to-consumer (DTC) advertising spending by the pharmaceutical industry was down by 1% compared to 2010. I did a little exercise to predict that DTC spending in 2012 will see a further 3% decrease compared to 2011 solely due to an expected drop in Lipitor advertising. Here's how I came up with that estimate.